Robotic Gait denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for robotic gait are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Robotic Gait Training as "Not FDA-Approved" — and Why You Can Appeal

Blue Cross Blue Shield plans frequently deny robotic-assisted gait training by categorizing it as investigational or by asserting that the specific device or system lacks FDA clearance for the claimed indication. This denial can be misleading: many robotic gait systems have received FDA 510(k) clearance for particular rehabilitation uses, yet payers may apply a blanket "not approved" rationale when the device is newer or when the clinical documentation does not explicitly link the device to its cleared indication. The gap between FDA device clearance and insurer coverage policy is a common source of wrongful denials.

## Your Appeal Rights

You have strong federal protections. Under ACA Section 2719, if your plan is non-grandfathered, you are entitled to an independent external review after exhausting internal appeals — typically a roughly four-month window from the date of denial. ERISA Section 503 requires that employer-sponsored plans provide a full-and-fair review of every adverse benefit determination. An expedited appeal is available if your condition is urgent or if waiting for standard review timelines would seriously jeopardize your health.

## The Appeal Process and Timeline

1. Request the denial in writing within days of receiving the verbal or electronic notice. The letter must state the specific reason and cite the plan provision relied upon. 2. File a first-level internal appeal — typically due within 180 days of denial. Submit all supporting documentation at this stage. 3. If the internal appeal is denied, request a second-level internal review if your plan offers one. 4. File for external review through your state insurance commissioner or the federal external review process (for self-funded ERISA plans). The external reviewer is an independent organization with no financial relationship to BCBS.

## Documentation to Gather

• Diagnosis confirmation: medical records establishing the underlying condition (e.g., stroke, spinal cord injury, acquired neurological impairment) that makes robotic gait training medically indicated.
• Prior treatment history: documented dates, providers, and outcomes of conventional physical therapy and other gait rehabilitation already attempted.
• Clinical severity: objective functional assessments from your chart — walking speed tests, balance scores, functional independence measures — showing the severity of your gait impairment and why standard therapy is insufficient.
• Prescriber medical-necessity letter: a detailed letter from your physiatrist, neurologist, or rehabilitation specialist explaining why robotic gait training is medically necessary for your specific condition, citing your functional deficits and expected rehabilitation goals.
• Device FDA clearance documentation: obtain the 510(k) clearance certificate or FDA product classification for the specific robotic system your provider uses. This directly refutes the "not FDA-approved" basis.
• Applicable clinical guidelines: reference guidance from the relevant rehabilitation medicine society or neurological organization (such as the applicable American Congress of Rehabilitation Medicine guideline) supporting robotic-assisted gait training for your diagnosis — without citing specific numbers.

## Criteria-Mapping Structure

For every requirement stated in BCBS's published coverage policy for rehabilitation technology, create a two-column table: the policy requirement in the left column, and the specific chart fact or document that satisfies it in the right column. Pay particular attention to how the policy defines "FDA clearance" — if it requires clearance for the specific indication rather than device class, document the cleared indication precisely and confirm your clinical use falls within it. This structure demonstrates that your case meets each criterion on its own terms and removes the reviewer's ability to deny on a technicality.